XML 15 R9.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities:    
Net loss $ (127,997) $ (126,222)
Adjustments to reconcile net loss to net cash used in operating activities:    
Non-cash royalty revenue related to the sales of future royalties (33,125) (48,029)
Non-cash interest expense on liabilities related to the sales of future royalties 16,415 17,959 [1]
Loss from equity method investment 7,381 0 [1]
Stock-based compensation 10,456 16,809
Depreciation and amortization expense 836 4,059
Impairment of right-of-use assets and property and equipment 0 8,329
Provision for net realizable value of inventory 0 20
Amortization of premiums (discounts), net (3,626) (7,711)
Changes in operating assets and liabilities:    
Accounts receivable 0 (841)
Inventory 0 (808)
Operating leases, net (9,407) (7,620)
Other assets (5,591) (1,761)
Accounts payable 4,168 (1,023)
Accrued expenses (3,062) 17,317
Net cash used in operating activities (143,552) (129,522)
Cash flows from investing activities:    
Purchases of investments (193,410) (191,882)
Maturities of investments 192,691 275,247
Purchases of property and equipment (153) (1,009)
Payment of transaction costs and working capital adjustment from the sale of the Huntsville manufacturing facility (697) 0
Net cash provided by (used in) investing activities (1,569) 82,356
Cash flows from financing activities:    
Proceeds from shares issued under equity compensation plans and other 456 35
Payments of offering costs associated with issuance of common stock (1,150) 0
Proceeds from issuance of pre-funded warrant 0 30,000
Proceeds from sale of future royalties 0 15,000
Repurchase of common stock from Bristol-Myers Squibb 0 (3,000)
Net cash provided by financing activities 141,895 42,035
Effect of foreign exchange rates on cash and cash equivalents 6 (37)
Net decrease in cash and cash equivalents (3,220) (5,168)
Cash and cash equivalents at beginning of period 44,252 35,277
Cash and cash equivalents at end of period 41,032 30,109
2025 Secondary Public Offering    
Cash flows from financing activities:    
Proceeds from offering, net 108,100 0
At-the-Market Offering    
Cash flows from financing activities:    
Proceeds from offering, net $ 34,489 $ 0
[1] All share and per share amounts have been retrospectively adjusted to reflect a one-for-fifteen reverse stock split (see Note 6).